Alcon Laboratories, Inc.

Gland Pharma Receives US FDA Approval for Latanoprost Ophthalmic Solution

6 months ago

• Gland Pharma has received US FDA approval for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), a generic equivalent to Xalatan. • The ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. • Gland Pharma plans to launch the product through its marketing partners in FY25, targeting a market with approximately $111.6 million in US sales. • This approval strengthens Gland Pharma's position in the US pharmaceutical market, expanding its portfolio of sterile injectable and ophthalmic solutions.